Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

Current diagnostic methods to determine programmed death 1 (PD-1) receptor and its ligand (PD-L1)/PD-1 immunotherapy (immune checkpoint inhibitor [ICI]) efficacy in recurrent or metastatic non–small-cell lung carcinoma (rmNSCLC) are imprecise. Although previously shown that patients with high tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Moran, Jillian A., Adams, Daniel L., Edelman, Martin J., Lopez, Pablo, He, Jianzhong, Qiao, Yawei, Xu, Ting, Liao, Zhongxing, Gardner, Kirby P., Tang, Cha-Mei, Lin, Steven H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166406/
https://www.ncbi.nlm.nih.gov/pubmed/36516370
http://dx.doi.org/10.1200/PO.22.00457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166406/
https://www.ncbi.nlm.nih.gov/pubmed/36516370
http://dx.doi.org/10.1200/PO.22.00457

Ejemplares similares